The Clinical Core of the Arizona ADCC is a consortium of five recruitment sites that function as a? standardized unit under a single Clinical Core Director. The Clinical Core maintains a target of 500? participants at all stages of the aging-dementia spectrum including 200 normal controls, 100 patients with? mild cognitive impairment (MCI), and 200 with Alzheimer's disease (AD) and other forms of degenerative? dementia. Embedded within these diagnostic categories are defined Latino and Native American cohorts.? The Clinical Core capitalizes on our multi-institutional diagnostic consensus conference, centralized data? management program, and close working relationships with each of the other Cores. It is intended to? capitalize on our multi-institutional collaborative model, address the challenges associated with a multi-site? core, and optimize the utilization of Clinical Core subjects and data in support of the unusually early? detection and tracking of AD, our strengths in brain imaging, cognitive neuroscience, neurogenomics, our? studies of several putative risk factors, and our participation in several national and international? collaboration projects. All subjects undergo standardized diagnostic testing that 1) fulfills strict entrance? criteria, 2) includes demographic, historical, medical, neurological, psychiatric, neuropsychological, and? genetic measures, 3) incorporates the NACC Uniform Data Set (UDS), and 4) employs culturally sensitive? test procedures. Patients eligible for enrollment and those completing annual follow-up are discussed in a? biweekly diagnostic consensus conference. All undergo apolipoprotein E (APOE) genotyping at entry, and? an annual standardized neuropsychological battery of tests at all sites. Patient eligibility for, and participation? in ongoing research projects is tracked and reviewed on an ongoing basis. All are offered enrolled in the? Brain Donation Program for neuropathological confirmation of clinical diagnoses, though brain donation is? not required of members of culturally sensitive diversity subgroups (Latino and Native Americans). The? particular strengths of the Clinical Core include:? 1. catchment areas throughout the state of Arizona based on a novel collaborative model that includes all? major tertiary care referral centers (BNI, MCA, SHRI, VA, UA)? 2. a scientific network of established collaborative relationships between Clinical Core neurologists and? biomedical researchers at all major research institutions in Arizona (and elsewhere)? 3. a Latino outreach program (through the collaborative efforts of the EIT and Clinical Cores) with a target? enrollment of at least 100 dementia/MCI patients and controls? 4. a Native American outreach program (through the collaborative efforts of the EIT and Clinical Cores) that? encourages the participation of Native Americans in the Clinical Core.? 5. ancillary programs of longitudinally studied aging normal controls also receive the NACC UDS supported? through other funding mechanisms. These cohorts provide unique opportunities to study the transition? between cognitive normality and MCI in persons at differential risk for AD and to capitalize on our strengths? in imaging, genomics, cognitive neuroscience, and other research methods. To address the goals of the? ADCC, subjects and data from independently funded projects are now available as a resource to other? researchers, being used in other studies, and will be followed prospectively using the UDS.?

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG019610-07
Application #
7460625
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
7
Fiscal Year
2007
Total Cost
$793,017
Indirect Cost
Name
Banner Sun Health Research Institute
Department
Type
DUNS #
960181055
City
Sun City
State
AZ
Country
United States
Zip Code
85351
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Sabbagh, Marwan N; Shi, Jiong; Lee, Moonhee et al. (2018) Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer's disease dementia from normal controls: preliminary findings. BMC Neurol 18:155
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Walker, Douglas G; Tang, Tiffany M; Lue, Lih-Fen (2018) Increased expression of toll-like receptor 3, an anti-viral signaling molecule, and related genes in Alzheimer's disease brains. Exp Neurol 309:91-106
Cabrera, Erwin; Mathews, Paul; Mezhericher, Emiliya et al. (2018) A? truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition. Biochim Biophys Acta Mol Basis Dis 1864:208-225
Wu, Jianfeng; Zhang, Jie; Shi, Jie et al. (2018) HIPPOCAMPUS MORPHOMETRY STUDY ON PATHOLOGY-CONFIRMED ALZHEIMER'S DISEASE PATIENTS WITH SURFACE MULTIVARIATE MORPHOMETRY STATISTICS. Proc IEEE Int Symp Biomed Imaging 2018:1555-1559
Tariot, Pierre N; Lopera, Francisco; Langbaum, Jessica B et al. (2018) The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's diseas Alzheimers Dement (N Y) 4:150-160
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Beach, Thomas G; Serrano, Geidy E; Kremer, Thomas et al. (2018) Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). J Neuropathol Exp Neurol 77:793-802

Showing the most recent 10 out of 794 publications